Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer.

Thoracic cancer - 1 Jan 2022

Zhang Min, Huang Chao, Zhou Huan, Liu Dan, Chen Runze, Li Xiuhua, Cheng Ye, Gao Bing, Chen Jun

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) has potential as a specific, noninvasive, and cost-effective new biomarker for patients with lung cancer. This study aimed to determine whether plasma ctDNA can be used to predict treatment outcomes in patients with lung cancer. METHODS: Pre- and in-treatment blood samples were collected from 14 patients with lung cancer receiving chemotherapy. Based on next-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Drug Therapy

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 34791810
DOI: 10.1111/1759-7714.14230
PMCID: PMC8720633

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer.PMID 34791810Read ↗

Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data.Semantic proximity Read ↗

Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patientsSemantic proximity Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Blood-based circulating tumor DNA mutations as a diagnostic and prognostic biomarker for lung cancer.Semantic proximity Read ↗

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.Semantic proximity Read ↗

Clinical utility of analyzing circulating tumor DNA in patients with non-small cell lung carcinomaSemantic proximity Read ↗

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.Semantic proximity Read ↗

Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.Semantic proximity Read ↗

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read ↗

Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.Semantic proximity Read ↗

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient ManagementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.